Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Biomea Fusion Inc (BMEA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: BMEA (1-star) is a SELL. SELL since 3 days. Profits (-31.56%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $18.25
1 Year Target Price $18.25
| 4 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -18.96% | Avg. Invested days 43 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 98.08M USD | Price to earnings Ratio - | 1Y Target Price 18.25 |
Price to earnings Ratio - | 1Y Target Price 18.25 | ||
Volume (30-day avg) 9 | Beta -0.25 | 52 Weeks Range 1.29 - 13.07 | Updated Date 07/2/2025 |
52 Weeks Range 1.29 - 13.07 | Updated Date 07/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.54 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -74.21% | Return on Equity (TTM) -156.81% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 70141270 | Price to Sales(TTM) - |
Enterprise Value 70141270 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.75 | Shares Outstanding 57022200 | Shares Floating 29253754 |
Shares Outstanding 57022200 | Shares Floating 29253754 | ||
Percent Insiders 9.76 | Percent Institutions 45.04 |
Upturn AI SWOT
Biomea Fusion Inc
Company Overview
History and Background
Biomea Fusion, Inc. is a biopharmaceutical company founded in 2018. It focuses on developing irreversible small molecule inhibitors to treat genetically defined cancers and metabolic diseases. The company is still in the clinical trial phase for their drug candidates.
Core Business Areas
- Drug Discovery and Development: Biomea focuses on discovering and developing irreversible inhibitors to address unmet needs in cancer and metabolic diseases.
- Clinical Trials: The company is currently conducting clinical trials for its lead drug candidate, particularly in the field of diabetes and oncology.
Leadership and Structure
Suriya Jayawardena is the CEO. The company has a management team focusing on research, clinical development, and business operations. They operate with a typical structure for a biotechnology company in the clinical trial phase.
Top Products and Market Share
Key Offerings
- BMF-219: BMF-219 is an irreversible menin inhibitor being developed for the treatment of diabetes and certain cancers. The market for diabetes and cancer treatments is vast with competitors like Novo Nordisk (NVO), Eli Lilly (LLY) in diabetes, and numerous large pharmaceutical companies in oncology. Market share data specific to BMF-219 is not yet available as it is still in clinical trials.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and research-intensive. There's a strong demand for innovative therapies, particularly in areas like cancer and diabetes. Regulatory hurdles and clinical trial risks are significant.
Positioning
Biomea Fusion is a clinical-stage company aiming to address unmet needs with irreversible inhibitors. Their competitive advantage lies in their novel approach targeting specific enzymes.
Total Addressable Market (TAM)
The TAM for diabetes and cancer therapies is substantial, estimated to be hundreds of billions of dollars globally. Biomea is positioned to capture a share of this market if their clinical trials are successful and their drug candidates are approved.
Upturn SWOT Analysis
Strengths
- Novel technology platform (irreversible inhibitors)
- Strong management team with experience in drug development
- Focus on high-value therapeutic areas (diabetes and cancer)
Weaknesses
- Early-stage clinical development (high risk)
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on successful clinical trial outcomes
Opportunities
- Potential for breakthrough therapies in diabetes and cancer
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline with new drug candidates
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- NVO
- LLY
- MRK
- AZN
Competitive Landscape
Biomea faces competition from established pharmaceutical companies with marketed therapies and other biotech companies developing novel treatments. Its success depends on demonstrating superior efficacy and safety in clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical development and advancing drug candidates into clinical trials.
Future Projections: Future growth is contingent on successful clinical trial results, regulatory approvals, and potential partnerships.
Recent Initiatives: Recent initiatives likely include advancing BMF-219 through clinical trials and exploring new drug candidates.
Summary
Biomea Fusion is a high-risk, high-reward clinical-stage biotech company. Their novel approach to targeting diseases with irreversible inhibitors offers promise. Clinical trial outcomes will be crucial for their success. They need to manage cash effectively and secure partnerships to advance their pipeline.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports (where available)
- Market research reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made based on thorough research and consultation with a financial advisor. Market share data are approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biomea Fusion Inc
Exchange NASDAQ | Headquaters San Carlos, CA, United States | ||
IPO Launch date 2021-04-16 | Interim CEO & Director Dr. Michael J. M. Hitchcock Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 79 | Website https://biomeafusion.com |
Full time employees 79 | Website https://biomeafusion.com | ||
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in San Carlos, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.